Clinical Trials
21 trialsThe DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study
First Hospital of China Medical University
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk
The First Affiliated Hospital with Nanjing Medical University
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
DoTH
Sun Yat-sen University
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
Shanghai Zhongshan Hospital
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
Anhui Provincial Hospital
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
Beijing Tsinghua Chang Gung Hospital
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Fudan University
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
Henan Cancer Hospital
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
Peking Union Medical College Hospital
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Fudan University
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd